Patent ID: 9289477
Filing Date: 2016-03-22
CPC Classification: A61K,A61P,B82Y,G01N,Y02A

Claim Text:
1. A composition comprising: (i) a first population of polymeric synthetic nanocarriers coupled to rapamycin, and (ii) a second population of polymeric synthetic nanocarriers coupled to antigens that comprise MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with an undesired CD8+ T cell immune response, wherein at least 75% of the polymeric synthetic nanocarriers of the first population of synthetic nanocarriers have a minimum dimension, obtained using dynamic light scattering, that is greater than 110 nm, and a maximum dimension, obtained using dynamic light scattering, that is equal to or less than 500 nm, wherein the load of the rapamycin on average across the first population of polymeric synthetic nanocarriers is at least 2% but no more than 25% (weight/weight), wherein the load of the antigens on average across the second population of polymeric synthetic nanocarriers is between 1% and 10% weight/weight, and wherein the composition is in an amount effective to reduce an undesired CD8+ T cell immune response.